Effects of Novel E-cigarette Constituents on Adults TCORS 3.0
Examining Appeal and Addiction Potential of Novel E-cigarette Constituents Among Adults
2 other identifiers
interventional
66
1 country
1
Brief Summary
This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 28, 2023
CompletedFirst Posted
Study publicly available on registry
July 6, 2023
CompletedStudy Start
First participant enrolled
June 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedDecember 26, 2025
December 1, 2025
11 months
June 28, 2023
December 23, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Liking: Score change in liking/wanting of each e-cigarette condition (5 conditions in total)
The Labeled Hedonic Scale will be used to ask about liking and wanting of the e-cigarette (one item Visual Analog Scale with ratings ranging from "most disliked sensation imaginable" to "most liked sensation imaginable" with higher values indicating greater liking).
Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)
Reinforcing Efficacy: Score change in drug effects of each e-cigarette condition (5 conditions in total)
Difference between e-cigarette effects for each e-cigarette condition as measured by the computerized version of the Drug Effects Questionnaire (DEQ). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. A modified version of the Drug Effects Questionnaire (DEQ) will be used in which participants rate acute responses to the e-cigarette on a 0-100mm scale from "not at all" (0mm) to "extremely" (100mm).
Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)
Irritation/Harshness: Score change in irritation of harshness of each e-cigarette condition (5 conditions in total)
Difference in irritation at each e-cigarette condition as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).
Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)
Secondary Outcomes (2)
Craving: Change in craving score for e-cigarette from baseline at each e-cigarette condition (5 conditions in total)
At baseline (at 0 minute), following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)
Changes of salivary Nicotine and Cotinine Levels from baseline at each e-cigarette condition (6 conditions in total)
At baseline (at 0 minute), Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)
Study Arms (18)
Non-menthol, nicotine 59mg/ml (1)
EXPERIMENTALFlavor without menthol with 59mg/ml nicotine
Low (0.1%) menthol, nicotine 59mg/ml (1)
EXPERIMENTALFlavor with low menthol concentration with 59mg/ml nicotine
High (2.0%) menthol, nicotine 59mg/ml (1)
EXPERIMENTALFlavor with high menthol concentration with 59mg/ml nicotine
Non-menthol, nicotine 59mg/ml (2)
EXPERIMENTALFlavor without menthol with 59mg/ml nicotine
Low (0.1%) menthol, nicotine 59mg/ml (2)
EXPERIMENTALFlavor with low menthol concentration with 59mg/ml nicotine
High (2.0%) menthol, nicotine 59mg/ml (2)
EXPERIMENTALFlavor with high menthol concentration with 59mg/ml nicotine
Non-menthol, nicotine 59mg/ml (3)
EXPERIMENTALFlavor without menthol with 59mg/ml nicotine
Low (0.1%) menthol, nicotine 59mg/ml (3)
EXPERIMENTALFlavor with low menthol concentration with 59mg/ml nicotine
High (2.0%) menthol, nicotine 59mg/ml (3)
EXPERIMENTALFlavor with high menthol concentration with 59mg/ml nicotine
Non-menthol, nicotine 59mg/ml (4)
EXPERIMENTALFlavor without menthol with 59mg/ml nicotine
Low (0.1%) menthol, nicotine 59mg/ml (4)
EXPERIMENTALFlavor low menthol concentration with 59mg/ml nicotine
High (2.0%) menthol, nicotine 59mg/ml (4)
EXPERIMENTALFlavor high menthol concentration with 59mg/ml nicotine
Non-menthol, nicotine 59mg/ml (5)
EXPERIMENTALFlavor without menthol with 59mg/ml nicotine
Low (0.1%) menthol, nicotine 59mg/ml (5)
EXPERIMENTALFlavor low menthol concentration with 59mg/ml nicotine
High (2.0%) menthol, nicotine 59mg/ml (5)
EXPERIMENTALFlavor high menthol concentration with 59mg/ml nicotine
Non-menthol, nicotine 59mg/ml (6)
EXPERIMENTALFlavor without menthol with 59mg/ml nicotine
Low (0.1%) menthol, nicotine 59mg/ml (6)
EXPERIMENTALFlavor low menthol concentration with 59mg/ml nicotine
High (2.0%) menthol, nicotine 59mg/ml (6)
EXPERIMENTALFlavor high menthol concentration with 59mg/ml nicotine
Interventions
Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.
Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.
Eligibility Criteria
You may qualify if:
- years or older
- Able to read and write
- Some current e-cigarette use
- Urine cotinine ≥200ng/ml
- Willing to abstain from tobacco/nicotine use 2 hours prior to sessions
You may not qualify if:
- Current use of non-prescription substances besides nicotine, marijuana, alcohol
- Any significant current medical or psychiatric condition
- Known hypersensitivity to propylene glycol
- Pregnant or lactating females
- Uncontrolled asthma
- Nut/e-liquid flavorant allergy
- Current marijuana (tetrahydrocannabinol) vaping + E-cigarette or vaping use Associated Lung Injury (EVALI) symptoms
- Dislike of menthol flavor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
JB Pierce Lab
New Haven, Connecticut, 06519, United States
Related Publications (1)
Lim J, Wood A, Green BG. Derivation and evaluation of a labeled hedonic scale. Chem Senses. 2009 Nov;34(9):739-51. doi: 10.1093/chemse/bjp054.
PMID: 19833660BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Suchitra Krishnan-Sarin, PhD
Yale University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Masking Details
- Participants will be given a nicotine containing e-cigarette that could have various levels of cooling flavoring. Participants will not be told the nicotine concentration of the product or the type or concentration of the added coolant or what order it is presented in. Investigator and research assistant (i.e. care provider) will know the doses of nicotine and coolant, but will not know what order coolants are presented to participants.
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 28, 2023
First Posted
July 6, 2023
Study Start
June 20, 2025
Primary Completion
May 1, 2026
Study Completion
May 1, 2026
Last Updated
December 26, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ANALYTIC CODE
- Time Frame
- The identifiable information will be kept for 7 years. After that, the data will become anonymous.
- Access Criteria
- The de-identified data will be made available for research purposes by contacting the PI.
We may share information about the IPD and study results with other researchers in the future, but the information will be de-identified.